Hong Kong SAR
-
The developer is looking to extend the maturity of its dollar bond by two years -
Chinese cancer immunotherapy drug producer parks over half of the deal with cornerstone investors
-
Gaush Meditech is seeking about $80m, and Weilong Global roughly $200m
-
Investors supported the deal, which allowed the group to replenish its funding at a lower cost
-
Chinese developers are facing legal action as outlook for the sector remains negative
-
-
-
Chinese insurance provider will start taking investor orders at the end of November
-
Chinese nickel producer's deal size takes a hit due to 'gloomy' market outlook
-
CoGard, Agile raise funding through ‘win-win’ deals but bankers warn market optimism may not last long
-
Another developer rushes to the equity capital market for funds
-
State-backed bank benefitted from a turn in sentiment towards Chinese credits
